Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease
12-Month Results From the IN.PACT SFA Randomized Trial

Gunnar Tepe, MD; John Laird, MD; Peter Schneider, MD; Marianne Brodmann, MD; Prakash Krishnan, MD; Antonio Micari, MD; Christopher Metzger, MD; Dierk Scheinert, MD; Thomas Zeller, MD; David J. Cohen, MD, MSc; David B. Snead, PhD; Beaux Alexander, MBA; Mario Landini, MS; Michael R. Jaff, DO; for the IN.PACT SFA Trial Investigators*

Background—Drug-coated balloons (DCBs) have shown promise in improving the outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated balloon with percutaneous transluminal angioplasty (PTA) for the treatment of symptomatic superficial femoral and popliteal artery disease.

Methods and Results—The IN.PACT SFA Trial is a prospective, multicenter, single-blinded, randomized trial in which 331 patients with intermittent claudication or ischemic rest pain attributable to superficial femoral and popliteal peripheral artery disease were randomly assigned in a 2:1 ratio to treatment with DCB or PTA. The primary efficacy end point was primary patency, defined as freedom from restenosis or clinically driven target lesion revascularization at 12 months. Baseline characteristics were similar between the 2 groups. Mean lesion length and the percentage of total occlusions for the DCB and PTA arms were 8.94±4.89 and 8.81±5.12 cm (P=0.82) and 25.8% and 19.5% (P=0.22), respectively. DCB resulted in higher primary patency versus PTA (82.2% versus 52.4%; P<0.001). The rate of clinically driven target lesion revascularization was 2.4% in the DCB arm in comparison with 20.6% in the PTA arm (P<0.001). There was a low rate of vessel thrombosis in both arms (1.4% after DCB and 3.7% after PTA [P=0.10]). There were no device- or procedure-related deaths and no major amputations.

Conclusions—In this prospective, multicenter, randomized trial, DCB was superior to PTA and had a favorable safety profile for the treatment of patients with symptomatic femoropopliteal peripheral artery disease.

Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique Identifiers: NCT01175850 and NCT01566461. (Circulation. 2015;131:495-502. DOI: 10.1161/CIRCULATIONAHA.114.011004.)

Key Words: drug-eluting balloons ■ peripheral arterial disease ■ peripheral vascular diseases

Endovascular treatment of symptomatic atherosclerotic peripheral artery disease (PAD) has gained widespread acceptance and is now recommended as the primary revascularization strategy in many clinical and anatomic scenarios.1−3 Percutaneous transluminal angioplasty (PTA) of the superficial femoral and popliteal artery has a high initial success rate, but restenosis occurs in up to 60% of cases.4 Although randomized trials have demonstrated patency rates with bare metal stents and drug-eluting stents superior to those observed with PTA,5−8 the optimal treatment for superficial femoral and popliteal artery disease remains controversial. Some practice guidelines advise against primary stenting in patients with intermittent claudication,9 whereas others recommend primary stenting in short- or intermediate-length lesions3 or

Clinical Perspective on p 502

Received May 5, 2014; accepted November 19, 2014.
From the RodMed Klinikum, Rosenheim, Germany (G.T.); UC Davis, Sacramento, CA (J.L.); Kaiser Permanente – Moanalua Medical Center and Clinic, Honolulu, HI (P.S.); Landeskrankenhaus – Universitätsklinikum, Graz, Austria (M.B.); The Mount Sinai Medical Center, New York, NY (P.K.); GVM Care and Research, Lugo, Italy (A.M.); Maria Eleonora Hospital, Palermo, Italy (A.M.); Wellmont Holston Valley Medical Center, Kingsport, TN (C.M.); Park-Krankenhaus Leipzig, Germany (D.S.); Universitäts-Herzzentrum Freiburg - Bad Krozingen, Germany (T.Z.); Saint Luke’s Mid America Heart Institute and University of Missouri-Kansas City School of Medicine, Kansas City, MO (D.J.C.); Medtronic, Inc., Santa Rosa, CA (D.B.S., B.A., M.L.); and Massachusetts General Hospital, Boston, MA (M.R.J.).

*The principal investigators and clinical sites participating in the IN.PACT SFA Randomized Trial are listed in the online-only Data Supplement.

The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.114.011004/-/DC1.

Correspondence to John R. Laird, MD, UC Davis Vascular Center, Lawrence J. Ellison Ambulatory Care Center, 4860 Y St, Suite 3400, Sacramento, CA 95817. E-mail john.laird@ucdmed.ucdavis.edu

© 2014 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer. This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIRCULATIONAHA.114.011004
in the event of acute PTA failure.\textsuperscript{1,2} Despite the improved outcomes reported in some trials with stenting, the dynamic stresses applied by the superficial femoral and popliteal artery may result in stent fracture\textsuperscript{10-11} or in-stent restenosis.\textsuperscript{12} Given the limitations of stenting, there has been considerable interest in identifying the approaches that could improve patency without the need for a permanent metallic implant.

One approach to this challenge has been the development of the drug-coated balloon (DCB), which combines balloon dilation with local delivery of an antiproliferative drug. Proof-of-concept evidence has demonstrated the utility of different DCB technologies in reducing both restenosis and the need for reintervention in comparison with PTA.\textsuperscript{13-17} Promising primary patency and target lesion revascularization rates up to 2 years postimplantation have been reported.\textsuperscript{18} However, robust evidence from large randomized, controlled trials is lacking. The IN.PACT SFA Trial was designed to test the safety and efficacy of the IN.PACT Admiral DCB for the treatment of patients with symptomatic PAD in the superficial femoral and proximal popliteal artery.

**Methods**

**Study Design**

The IN.PACT SFA Trial is a multicenter, international, single-blinded, randomized, controlled trial to assess the safety and efficacy of the IN.PACT Admiral DCB (Medtronic Inc, Santa Rosa, CA) versus standard PTA balloons in patients with symptomatic superficial femoral and proximal popliteal artery disease. The trial was prospectively designed to be conducted in 2 phases: IN.PACT SFA I (conducted in Europe) and IN.PACT SFA II (conducted in the United States), which are jointly referred to as IN.PACT SFA. The IN.PACT SFA Trial was prospectively analyzed according to a single statistical analysis plan. The 2 phases occurred sequentially in time with enrollment completed in the IN.PACT SFA I phase before the initiation of the IN.PACT SFA II phase. Minor differences between the IN.PACT SFA I phase and the IN.PACT SFA II phase eligibility criteria exist and include subtle variations in concomitant inflow and contralateral limb treatment, along with differences in predilation requirements. A prespecified poolability test for treatment-by-trial phase interaction was established, with planned data pooling across the 2 phases in the event that there was no significant treatment-by-trial interaction.

Both protocols were approved by the institutional review boards or ethics committees at each trial site. All patients provided written informed consent before enrollment. Both trial phases were conducted in accordance with the Declaration of Helsinki, good clinical practice guidelines, and applicable laws as specified by all relevant governmental bodies.

An independent clinical events committee adjudicated all major adverse events. Independent core laboratories analyzed all images, including duplex ultrasonography (VascCore, Massachusetts General Hospital, Boston, MA) and angiography (SynvaCor, Springfield, IL).

**Patient Population**

Patients were eligible for enrollment if they had moderate to severe intermittent claudication or ischemic rest pain (Rutherford 2–4) and stenosis of 70% to 99% with lesion lengths between 4 and 18 cm or occlusion with lengths of ≤10 cm involving the superficial femoral and proximal popliteal arteries, and met all other eligibility criteria.

**Randomization and Blinding**

Randomization occurred after successful crossing of the lesion in the IN.PACT SFA I phase and after successful crossing and predilation with a standard PTA balloon 1 mm smaller than the reference vessel diameter in the IN.PACT SFA II phase. A patient was considered enrolled at the time of randomization. Subjects were randomly assigned by an Interactive Voice Response System with the use of a method of permuted blocks to ensure that a 2:1 ratio was maintained across sites (Figure 1).

The patients and the trial sponsor were blinded to the treatment assignments through the completion of all 12-month follow-up evaluations. The independent core laboratories and clinical events committee will remain blinded to the treatment assignments throughout the 60-month follow-up duration. Because of the visual difference between the IN.PACT DCB and standard PTA balloon, treating physicians, research coordinators, and catheterization laboratory staff were not blinded to the treatment assignment. Treating physicians, research coordinators, and catheterization laboratory staff received detailed and specific instructions and training on how to preserve the patients’ blinded status.

**Treatment and Medical Therapy**

Patients randomly assigned to the experimental arm were treated with the IN.PACT Admiral DCB. The IN.PACT DCB has a dual mode of action, comprising mechanical dilatation by the angioplasty balloon plus local drug delivery to the arterial wall intended to inhibit restenosis. The IN.PACT DCB coating includes paclitaxel as the antiproliferative agent at a dose of 3.5 μg/mm², with urea as the excipient. Available IN.PACT Admiral DCB sizes included 4-, 5-, 6-, and 7-mm diameters and 20-, 40-, 60-, 80 and 120-mm lengths (the 7-mm diameter device was not available in the 120-mm length). A minimum balloon inflation time of 180 seconds was required for both treatment groups. To avoid geographic miss, DCB length was chosen to exceed the target lesion length by 10 mm at the proximal and distal edges. The IN.PACT DCB is a single-inflation device, and, when treatment required multiple balloons, an overlap of 10 mm was applied for contiguous balloon inflations.

Premedication included a loading dose of aspirin 300 to 325 mg and clopidogrel 300 mg within 24 hours of the index procedure or 2 hours postprocedure. Heparin was administered at the time of the procedure to maintain an activated clotting time ≥250 seconds.

![Figure 1. Trial flow diagram. The IN.PACT SFA Trial used a 2:1 randomized, control design, and intent-to-treat (ITT) analysis was conducted at 12 months. Three hundred thirty-one (331) patients with de novo or nonstented restenotic lesions in the superficial femoral and proximal popliteal artery were randomly assigned either to the IN.PACT Admiral drug-coated balloon or standard PTA treatment group. All subjects enrolled in the IN.PACT SFA Trial (n=331) will be followed for up to 5 years. Analysis at 1 year included subjects that provided end point data at the time of data snapshot. A subject was excluded under the following circumstances: (1) consent was withdrawn before the 1-year visit and no event had occurred before withdrawal or (2) there was no contact with the subject permitting a 1-year evaluation and no events had occurred before the 1-year evaluation. DCB indicates drug-coated balloon; PTA, percutaneous transluminal angioplasty; and SFA, superficial femoral artery.](image-url)
Postdilatation with a standard PTA balloon was allowed at the discre-
tion of the operator. In both treatment groups, provisional stenting
was allowed only in the case of PTA failure after repeated and pro-
longed PTA inflations. PTA failure was defined as a residual stenosis
\( \geq 50\% \) or major (2 grade D) flow-limiting dissection confirmed by a
peak translesional systolic pressure gradient of \( > 10 \text{ mm Hg} \).

In both arms, postprocedure medical therapy included aspirin 81
to 325 mg daily (for a minimum of 6 months) and clopidogrel 75
mg daily for a minimum duration of 1 month for nonstenented
patients and 3 months for patients who received stents. Usage of aspirin and
antiplatelet drugs did not differ between treatment arms at discharge
(97.6\%), 30 days (87.6\%), or 12 months (51.5\%).

Follow-Up

For the primary end point analysis, patients were followed by the
treating physician at 30 days, 6 months, and 12 months, including
office visits with duplex ultrasonography functional testing and
adverse event assessment. Reinterventions, if required within 12
months of the procedure, were performed according to standard prac-
tice by using PTA balloons and provisional stenting.

Study End Points

The primary efficacy end point was primary patency at 12 months
following the index procedure, defined as freedom from clinically
driven target lesion revascularization and restenosis as determined by a
duplex ultrasonography–derived peak systolic velocity ratio of
\( \leq 2.4 \). Each component of the primary efficacy end point was inde-
pendently adjudicated by the blinded Clinical Events Committee (for
clinically driven target lesion revascularization) or by the core labo-
ratories (for restenosis). Specifically, the independent Clinical Events
Committee determined whether reinterventions at the target lesion
were clinically driven on the basis of objective testing (ankle-brachial
index decrease \( \geq 20\% \) or \( > 0.15 \) in comparison with postprocedure
ankle-brachial index) or symptoms of exertional limb discomfort.

Safety end points included 30-day device- and procedure-related
death, all-cause death, major target limb amputation, and target ves-
sel thrombosis. These events were site reported and Clinical Events
Committee adjudicated. Additional efficacy end points included acute
procedural success, target vessel revascularization at 12 months, and
primary sustained clinical improvement (defined as freedom from
target limb amputation, target vessel revascularization, and increase
in Rutherford class \( \geq 1 \) at 12 months). Functional assessments included
general appraisal through administration of a 5-dimension (EQ-5D)
health-related quality-of-life questionnaire and specific evaluation of
walking capacity by using a Walking Impairment Questionnaire. A
Six-Minute Walk Test was additionally conducted in the IN.PACT
SFA II phase only.

Statistical Analysis

The planned enrollment of 330 subjects provided a power of 80% to
detect a 50% improvement in the primary end point at 12 months
(from 40% in the PTA group to 60% in the DCB group) with a
1-sided type I error of 2.5%. From its inception, the trial was intended
to have 2 phases under a single statistical analysis plan. Poolability of
subjects across trial phases for the primary end point analysis was
tested by using Cox proportional hazards regression. For this poola-
bility analysis, model covariates included treatment group, phase,
and a treatment-by-phase interaction effect. Because the treatment-
by-trial phase interaction value for the primary end point was non-
significant \( (P=0.428) \), the 2 trial phases were pooled for all analyses.

All analyses were based on the intention-to-treat principle. Continuous variables are described as mean±standard deviation and
were compared by \( t \) tests. Categorical variables are described as proportions and were compared by the \( Z \) test owing to the 1-sided
testing. The \( Z \) test was used to test the hypothesis of equality of pro-
portions in achieving the primary end point. Multiple imputation was
performed by using the logistic regression approach for patients with
missing primary end point data (29 DCB, 7 PTA). The following vari-
ables were included in the imputation model as covariates: age, sex,
diabetes mellitus, lesion length, total occlusion, and Rutherford class
at baseline. Five data sets were imputed from these covariates that
mimic different realizations of the missing data. Within each imputed
data set for the end point, the proportion experiencing the end point
was statistically compared between treatment groups by using the
2-sample \( Z \) test. From these, an overall test statistic for the end point
and its associated \( P \) value were calculated for the imputed data. The
imputed difference (95% confidence interval) and \( P \) value are reported
along with the as-observed numerator and denominator. A sensitivity
analysis of the as-observed rates revealed a similar highly significant
\( P \) value \( (P<0.001) \). As a secondary analysis, clinically driven target
lesion revascularization was analyzed by the Kaplan-Meier method
during the 12-month follow-up period. The difference in the survival
curves between groups was assessed by using log-rank statistics.

Statistical analyses were performed using SAS (SAS Institute, Cary,
NC) version 9.2 or higher. Additional statistical information is found in
Appendix I in the online-only Data Supplement.

Role of the Funding Source

The trial was designed by the principal investigators (G.T., J.L., P.S.)
and the sponsor (Medtronic). The data were collected and analyzed
by the sponsor. Harvard Clinical Research Institute independently
validated the analyses, with funding from the sponsor. The first and
last authors prepared the first draft, which was then reviewed and
edited by the other coauthors. The sponsor had the right to review but
not to approve the final manuscript. The authors had full access to
all data and accept full responsibility for the accuracy and complete-
ness of the reported analyses and interpretations of the data, and they
vouch for the fidelity of the study to the protocol (available with full
text of this article at http://circ.ahajournals.org/).

Results

Baseline and Procedural Characteristics

Between September 2010 and April 2011 (IN.PACT SFA I
phase) and between April 2012 and January 2013 (IN.PACT
SFA II phase), 331 patients (220 in the DCB group and
111 in the PTA group) were enrolled at 13 sites in Europe
and 44 sites in the United States, respectively. Patient flow
through the 12-month follow-up is described in Figure 1. Demographics, comorbidities, and lesion characteristics
were similar between the DCB and PTA groups (Table 1).

The mean lesion length was 8.94±4.89 in the DCB arm
and 8.81±5.12 cm in the PTA arm \( (P=0.82) \). Occlusions were
treated in 25.8% and 19.5% \( (P=0.22) \) of patients in the DCB
and PTA arms, respectively. No significant differences across
the 2 arms were observed, with the exception of a lower num-
er of patent infrapopliteal runoff vessels in the PTA group
\( (P=0.04) \). Adjustment for differences in runoff between the
treatment groups using propensity scores had no impact on
the primary efficacy and safety outcomes.

Efficacy Outcomes

Procedural success, defined as a residual diameter stenosis of
\( \leq 50\% \) for nonstenented patients or \( \leq 50\% \) for stented patients,
was achieved in 99.5% of subjects in the DCB arm and 98.2%
of subjects in the PTA arm.

In the intention-to-treat population, the 12-month primary
patency rate was 82.2% in the DCB arm versus 52.4% in the PTA
arm \( (P<0.001; \text{ Table 2}) \). The DCB-treated patients demonstrated
lower rates of clinically driven target lesion revascularization ver-
sus PTA-treated patients through 12 months (2.4% versus 20.6%;
\( P<0.001; \text{ Figure 2}) \). A significantly higher primary sustained
clinical improvement (85.2%) was observed in the DCB arm in
### Table 1. Baseline and Procedural Characteristics – All Intention-to-Treat Subjects

|                      | DCB (n=220 Subjects n=221 Lesions) | PTA (n=111 Subjects n=113 Lesions) | PValue* |
|----------------------|------------------------------------|------------------------------------|---------|
| **Clinical characteristics** |                                    |                                    |         |
| Age, y†              | 67.5±9.5                           | 68.0±9.2                           | 0.61    |
| Male sex,‡ (% m/n)   | 65.0 (143/220)                     | 67.6 (75/111)                      | 0.71    |
| Diabetes mellitus, % (m/n) | 40.5 (89/220)                     | 48.6 (54/111)                      | 0.16    |
| Hypertension, % (m/n) | 91.4 (201/220)                     | 88.3 (99/111)                      | 0.43    |
| Hyperlipidemia, % (m/n) | 84.5 (186/220)                     | 82.0 (91/111)                      | 0.64    |
| Current smoker, % (m/n) | 38.6 (85/220)                     | 36.0 (40/111)                      | 0.72    |
| Coronary artery disease, % (m/n) | 57.0 (122/214)                     | 55.0 (60/109)                      | 0.81    |
| Carotid artery disease, % (m/n) | 34.9 (73/209)                     | 31.7 (32/101)                      | 0.61    |
| ABI / TBI§           | 0.769±0.228                        | 0.744±0.189                        | 0.31    |
| Rutherford class, % (m/n) | 57.3 (126/220)                     | 55.9 (62/111)                      | 0.90    |
| 2                    | 37.7 (83/220)                      | 37.8 (42/111)                      |         |
| 3                    | 57.3 (126/220)                     | 55.9 (62/111)                      |         |
| 4                    | 5.0 (11/220)                       | 5.4 (6/111)                        |         |
| 5                    | 0.0 (0/220)                        | 0.9 (1/111)                        |         |
| **Angiographic characteristics** |                                    |                                    |         |
| Lesion type – de novo,¶ % (m/n) | 95.0 (209/220)                     | 94.6 (105/111)                     | 0.88    |
| No. of patent runoff vessels, % (m/n) | 3.3 (7/212)                        | 4.5 (5/112)                        | 0.04    |
| 0                    | 3.3 (7/212)                        | 4.5 (5/112)                        |         |
| 1                    | 13.7 (29/212)                      | 26.8 (30/112)                      |         |
| 2                    | 41.5 (88/212)                      | 33.0 (37/112)                      |         |
| 3                    | 41.5 (88/212)                      | 35.7 (40/112)                      |         |
| Proximal popliteal involvement, % (m/n) | 6.8 (15/221)                       | 7.1 (8/113)                        | 1.00    |
| Lesion length,¶ cm   | 8.9±4.89                           | 8.8±5.12                           | 0.82    |
| Total occlusions, % (m/n) | 25.8 (57/221)                      | 19.5 (22/113)                      | 0.22    |
| Severe calcification, % (m/n) | 8.1 (18/221)                       | 6.2 (7/113)                        | 0.66    |
| Reference vessel diameter, mm | 4.647±0.841                        | 4.681±0.828                        | 0.73    |
| Minimum lumen diameter (preprocedure), mm | 0.900±0.776                        | 0.933±0.771                        | 0.71    |
| Diameter stenosis (preprocedure), % | 81.1±15.5                           | 81.3±13.7                          | 0.95    |
| **Procedural characteristics** |                                    |                                    |         |
| Predilatation, % (m/n) | 96.4 (212/220)                      | 85.6 (95/111)                      | <0.001  |
| Postdilatation, % (m/n) | 26.8 (59/220)                      | 18.9 (21/111)                      | 0.14    |
| No. of treatment balloons per subject | 1.4±0.7                            | 1.1±0.3                            | <0.001  |
| First treatment balloon maximum pressure, atm | 8.3±2.1                            | 8.6±2.1                            | 0.12    |
| Dissections, % (m/n) | 36.2 (80/221)                      | 38.9 (44/113)                      | 0.36    |
| 0                    | 36.2 (80/221)                      | 38.9 (44/113)                      |         |
| A–C                  | 63.8 (141/221)                     | 60.2 (68/113)                      |         |
| D–F                  | 0.0 (0/221)                        | 0.9 (1/113)                        |         |

### Table 1. Continued

|                      | DCB (n=220 Subjects n=221 Lesions) | PTA (n=111 Subjects n=113 Lesions) | PValue* |
|----------------------|------------------------------------|------------------------------------|---------|
| Provisional stenting, % (m/n) | 7.3 (16/220)                      | 12.6 (14/111)                      | 0.11    |
| Minimum lumen diameter (postprocedure), mm | 3.903±0.750                      | 3.862±0.732                        | 0.63    |
| Diameter stenosis (postprocedure), % | 19.9±10.4                           | 19.1±10.3                          | 0.54    |
| Device success,¶ % (m/n) | 99.0 (308/311)                      | 98.5 (128/130)                      | 0.30    |
| Procedural success,** % (m/n) | 99.5 (219/220)                      | 98.2 (109/111)                      | 0.11    |
| Clinical success,¶¶ % (m/n) | 99.1 (218/220)                      | 97.3 (108/111)                      | 0.10    |

*All P values are 2-sided with the exception of success outcomes, which use 1-sided P values.
†Values represent mean±SD.
‡Based on number of intention-to-treat subjects with available data.
§TBI allowed / used in cases of incompressible vessels in IN.PACT SFA II Trial phase.
¶Normal-to-normal by Core Laboratory quantitative vascular angiography evaluation.
#Successful delivery, inflation, deflation, and retrieval of the intact trial balloon without burst < rated burst pressure.
**No procedural complications (death, major target limb amputation, thrombosis of target lesion, or target vessel revascularization) before discharge.
¶¶Residual diameter stenosis ≤50% for nonstented subjects or ≤30% for stented subjects.

comparison with the PTA arm (68.9%; P<0.001). The ankle-brachial index was significantly higher in the DCB arm at 12 months (Table 2). Implantation of provisional stents was similar in the DCB and PTA arms (7.3% versus 12.6%; P=0.11). When stented patients were excluded from the analyses, there were no changes in any of the conclusions. Efficacy outcomes by trial phase are included in Table I in the online-only Data Supplement.

### Safety Outcomes

There were no procedure- or device-related deaths and no major amputations through 12 months in either arm. Site-reported and Clinical Events Committee–adjudicated vessel thrombosis occurred in 1.4% of the subjects in the DCB arm and 3.7% of the subjects in the PTA arm (P=0.10). All-cause death through 12 months was 1.9% (n=4) versus 0.0% (n=0) in the DCB and PTA arms (7.3% versus 12.6%; P=0.11). When stented patients were excluded from the analyses, there were no changes in any of the conclusions. Efficacy outcomes by trial phase are included in Table I in the online-only Data Supplement.

### Functional Outcomes

At 12 months, there was no significant difference between treatment groups in the change from baseline in quality-of-life by using the EQ-5D assessment, but the results trended in
favor of IN.PACT DCB ($P=0.10, 0.1059$ versus $0.0730$). Both treatment groups also showed improvement from baseline in walking impairment at 12 months. Although the treatment groups showed similar functional outcomes at 12 months, 8.6 times more of the PTA subjects required a clinically driven target lesion revascularization to achieve the same levels of functional outcomes as the IN.PACT Admiral DCB subjects. In the IN.PACT SFA II phase, both treatment groups also showed improvement from baseline to 12 months in the walking distance assessed by the 6-Minute Walk Test, with no statistically significant difference between treatment groups. Functional outcomes by trial phase are included in Table I in the online-only Data Supplement.

### Discussion

In this trial, the IN.PACT Admiral drug-coated balloon resulted in superior efficacy in comparison with a plain angioplasty balloon for the treatment of patients with symptomatic superficial femoral and proximal popliteal PAD. There was significantly better primary patency and a marked reduction in the need for target lesion revascularization at 12 months following treatment with the DCB.

The efficacy of paclitaxel in reducing restenosis in the femoropopliteal artery has been previously reported by the use of different DCB technologies in various trials.$^{13-18}$ Although paclitaxel was the most commonly used antiproliferative drug in these preceding trials, each DCB was unique with respect to the paclitaxel dose (varying from 2 to $3.5 \mu g/mm^2$), the carrier molecule (excipient), the balloon material, and the balloon and coating technology used. The findings from the present trial are consistent with these previous DCB proof-of-concept trials$^{13-16}$ that, although smaller because they were powered on a 6-month angiographic end point, enrolled a similar patient population with symptomatic femoropopliteal disease. All of these trials demonstrated significant reductions in late lumen loss at 6 months and lower rates of target lesion revascularization at 1 year for DCB versus PTA.$^{13-16}$

Moreover, the IN.PACT SFA Trial results are concordant with the 83.7% primary patency at 1 year reported by Micari et al$^{20}$ from a multicenter registry of IN.PACT DCB use in a similar patient population.

Numerous modalities are available for the treatment of superficial femoral and popliteal artery disease, including implant-based technologies such as bare metal stents.$^{5-7,20,21}$

### Table 2. Key Clinical and Safety Outcomes

| Outcome | DCB (n=220) | PTA (n=111) | Difference [95% CI]* | $P$ Value † |
|---------|-------------|-------------|----------------------|-------------|
| Primary efficacy – primary patency,‡ % (m/n) | 82.2 (157/191) | 52.4 (54/103) | 26.2% [15.1%–37.3%] | <0.001 |
| 12-month efficacy outcomes | | | | |
| All TLR, % (m/n) | 2.9 (6/207) | 20.6 (22/107) | <0.001 |
| Clinically driven TLR,§ % (m/n) | 2.4 (5/207) | 20.6 (22/107) | <0.001 |
| Clinically driven TVR, % (m/n) | 4.3 (9/207) | 23.4 (25/107) | <0.001 |
| Primary sustained clinical improvement,|| % (m/n) | 85.2 (167/196) | 68.9 (73/106) | <0.001 |
| ABI/TBI* | 0.951±0.221# | 0.886±0.169 | 0.002 |
| 12-month safety outcomes | | | | |
| 30-day device- and procedure-related death, % (m/n) | 0.0 (0/218) | 0.0 (0/111) | >0.999 |
| Target limb major amputation, % (m/n) | 0.0 (0/207) | 0.0 (0/107) | >0.999 |
| All-cause death, % (m/n) | 1.9 (4/207) | 0.0 (0/107) | 0.93 |
| Thrombosis,** % (m/n) | 1.4 (3/207) | 3.7 (4/107) | 0.10 |
| 12-month functional outcomes | | | | |
| Change from baseline by EQ-5D Index | 0.1059±0.2089# | 0.0730±0.1951 | 0.095 |
| Walking impairment, % | 72.7±31.4# | 73.6±29.5 | 0.590 |
| Change in 6MWT from baseline to 12 mo,‡‡ m | 38.7±92.1# | 59.1±102.3 | 0.878 |

*Based on multiple imputation of missing data.  †One-sided $P$ value. ‡Based on number of subjects with available data (ie, as observed). §Clinically driven TLR adjudicated by an independent Clinical Events Committee that was blinded to the assigned treatment, based on any reintervention at the target lesion attributable to symptoms or drop of ABI of ≥20% or >0.15 in comparison with postprocedure baseline ankle-brachial index. ||Freedom from target limb amputation, TVR, and increase in Rutherford class at 12 months postprocedure. ††ABI allowed/used in cases of incompressible vessels in IN.PACT SFA II.  #Values represent mean±SD. **Defined as an occlusion attributable to thrombus formation that is rapidly evolving as confirmed by the sudden onset of symptoms within 14 days of imaging, and documented by duplex ultrasound and angiography of the index vessel.  ‡‡Data collected in IN.PACT SFA II phase only.
covered stents,22,23 and drug-eluting stents,8,24 and implant-free technology, as well, such as atherectomy devices.25 DCB is an attractive alternative because it offers the promise of improved patency in comparison with PTA and a reduction in the need for stents. This is particularly important in the dynamic environment of the superficial femoral and popliteal arteries, where mechanical fatigue may lead to stent fracture and increased risk of in-stent restenosis.10−11 Restenosis following superficial femoral and popliteal artery stenting has been reported to occur in recent trials with a frequency of ≥20% at 12 months with higher rates of ≥50% following stenting of long-segment disease.12,20,21,26 Diffuse in-stent restenosis or in-stent occlusion is a very difficult problem to treat,12,26,27 with recurrent restenosis rates of >70% at 1 to 2 years, although recent results have suggested improved outcomes with peripheral drug-eluting stents28 and DCB.29,30 Use of a DCB (and avoidance of stent implantation) does not limit future treatment options, an important consideration given the chronic and progressive nature of PAD.

These findings compare favorably with other randomized clinical trials in this patient population. Despite the inclusion of longer lesion lengths that are at a higher risk of treatment failure, the 2.4% target lesion revascularization rate experienced in this trial is the lowest reported for an SFA device trial at 12 months. Clinically driven target lesion revascularization rates of 12.7% and 9.5% were reported in 2 recent randomized trials of bare metal and drug-eluting stents, despite their inclusion of shorter lesions (average lesion lengths of 7.0 and 5.4 cm, respectively).31 IN.PACT DCB was associated with a low complication rate, including the absence of major amputations and a low rate of vessel thrombosis.

Study Limitations
The trial was deliberately and prospectively conducted in 2 sequential phases. The blinding of phase I was rigorously maintained until the completion of phase II. When the data were analyzed, there were no statistical differences between the 2 phases.

Although improvements in the functional assessments of quality of life, walking impairment, and walking distance were observed in both treatment groups, the interpretation of these measures is complicated by the subjective nature of patient questionnaires and the influence of comorbidities, including progressive disease in nontreated vessels.

The results of this trial cannot be generalized to patients not included in this trial. Future studies should encompass longer lesions and consider comparison with bare metal stents, drug-eluting stents, and bypass, and optimal medical therapy and exercise, as well. Longer-term follow-up is needed to confirm the durability of the benefit.

Conclusions
In conclusion, in this large, prospective, multicenter, international, randomized trial, DCB was superior to PTA and had a favorable safety profile for the treatment of patients with symptomatic superficial femoral and proximal popliteal artery PAD. The IN.PACT DCB demonstrated impressive patency rates with low repeat revascularization rates in comparison with other modern endovascular therapies. DCB stands to become an important treatment option for patients with superficial femoral and popliteal artery disease.

Acknowledgments
We thank Judith Greengard, Victoria Rendon, and Melissa Hasenbank for editing assistance. Contributions: Drs Tepe, Iaff, and Laird prepared the first draft of this manuscript, which was then reviewed and edited by the other coauthors. Drs Snead and Cohen undertook the statistical analysis. All the authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; and also contributed to drafting the article or revising it critically for important intellectual content.

Source of Funding
The study was funded by Medtronic, Inc.

Disclosures
Dr Tepe holds research grants from Bard Peripheral Vascular, B. Braun, Biotronic, Covidien, Medrad, and Medtronic. He is a compensated advisory board member for Medtronic, and receives speaking honoraria from Bard Peripheral Vascular, Biotronic, Covidien,
Medrad, and Medtronic. Dr Laird holds research grants from W.L. Gore and Medtronic. He is a compensated advisory board member and consultant for Abbott Vascular, Bard Peripheral Vascular, Boston Scientific, Cividien, and Medtronic. Dr Micari holds research grants from Medtronic, and is a compensated consultant for Medtronic. Dr Metzger receives speaking honoraria from Bard Peripheral Vascular and Medtronic and is compensated for participation in training courses sponsored by Abbott Vascular and Medtronic. He is a compensated consultant for Abbott Vascular. Dr Scheinert holds research grants from Abbott Vascular, Angiosite, Atheromed, Biotronik, Boston Scientific, Cook Medical, Cordis, Cividien, CR Bard, Gardia Medical, Heotech, Intact Vascular, Medtronic, TriReme Medical, and Upstream Peripheral Technologies. He is a compensated consultant on advisory board for Abbott Vascular, Angiosite, Atheromed, Biotronik, Boston Scientific, Cook Medical, Cordis, Cividien, CR Bard, Gardia Medical, Heotech, Intact Vascular, Medtronic, TriReme Medical, and Upstream Peripheral Technologies. Dr Zeller holds research grants from Bard-Lutonix, Biontronik, Cook Medical, and Medtronic. Dr Cohen holds research grants from Abbott Vascular, Boston Scientific, Cividien, and Medtronic and is a compensated consultant for Abbott Vascular and Medtronic. Dr Snead, B. Alexander, and M. Landini are full-time employees of Medtronic. Dr Jaff is a noncompensated Advisor for Medtronic and is the Medical Director of VasCore, the Vascular Ultrasound Core Laboratory. He is a compensated member of VIVA Physicians, a not-for-profit 501(c)3 education/research organization. The other authors report no conflicts.

References

1. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL.

Tepe et al Drug-Coated Balloons for SFA Disease

501
TASC C and D femoropopliteal lesions. J Vasc Surg. 2011;54:1042–1050. doi: 10.1016/j.jvs.2011.03.272.

21. Armstrong EJ, Saeed H, Alvandi B, Singh S, Singh GD, Yeo KK, Anderson D, Westin GG, Dawson DL, Pevec WC, Laird JR. Nitinol self-expanding stents vs. balloon angioplasty for very long femoropopliteal lesions. J Endovasc Ther. 2014;21:34–43. doi: 10.1583/13-4399MR.1.

22. Saxon R, Chervu A, Jones P, Bajwa TK, Gable DR, Soukas PA, Begg RJ, Adams JG, Ansel GM, Schneider DB, Eichler CM, Rush MJ. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial. J Vasc Interv Radiol. 2013;24:165–174.

23. Lammer J, Zeller T, Hausegger K, Schaefer PJ, Gschwendtner M, Mueller-Huelsbeck S, Rand T, Funovics M, Wolf F, Rastan A, Gschwandtner M, Puchner S, Ristik R, Schoeder M. Heparin-bonded covered stents versus bare metal stents for complex femoro-popliteal artery lesions: the randomized VIASTAR trial. J Am Coll Cardiol. 2013;62:1320–1327. doi: 10.1016/j.jacc.2013.05.079.

24. Dake MD, Scheinert D, Tepe G, Tessarek J, Fanelli F, Bosiers M, Ruhlmann C, Kavteladze Z, Lottes AE, Ragheb AO, Zeller T; Zilver PTX Single-Arm Study Investigators. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther. 2011;18:613–623. doi: 10.1583/11-3560.1.

25. Garcia LA, Lyden SP. Atherectomy for infrainguinal peripheral artery disease. J Endovasc Ther. 2009;16(suppl 2):II105–15.

26. Tosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K, Yokoi H, Nanto S, Nobuyoshi M. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16–23. doi: 10.1016/j.jacc.2011.09.036.

27. Laird JR Jr, Yeo KK, Rocha-Singh K, Das T, Joyce J, Dippel E, Reddy B, Botti C, Jaff MR. Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the SALVAGE study. Catheter Cardiovasc Interv. 2012;80:852–859. doi: 10.1002/ccd.23475.

28. Zeller T, Dake MD, Tepe G, Brechtel K, Noory E, Beschonger U, Kultgen PL, Rastan A. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv. 2013;6:274–281. doi: 10.1016/j.jcin.2012.12.118.

29. Virga V, Stabile E, Biamino G, Saleemne L, Cioppa A, Giugliano G, Tesorio T, Cota L, Popusoi G, Pucciarelli A, Esposito G, Trimarco B, Rubino P. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up. JACC Cardiovasc Interv. 2014;7:411–415. doi: 10.1016/j.jcin.2013.11.020.

30. Liistro F, Angioli P, Porto I, Ricci L, Ducci K, Grotti S, Falsini G, Ventoruzzo G, Turini F, Bellandi G, Bolognese L. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study. J Endovasc Ther. 2014;21:1–8. doi: 10.1583/13-4420R.1.

CLINICAL PERSPECTIVE

The clinical data from the IN.PACT SFA Trial, which was designed as a 2-phase, global, multicenter, single-blind, randomized trial, provide valid scientific evidence to conclusively demonstrate the effectiveness and safety of the IN.PACT Admiral Drug-Coated Balloon (DCB) in the treatment of patients with peripheral artery disease in the superficial femoral and proximal popliteal artery. The IN.PACT Admiral DCB achieved the primary effectiveness and safety end points of the trial, demonstrating superiority of IN.PACT Admiral DCB to percutaneous transluminal angioplasty. Despite the inclusion of longer lesion lengths that are at a higher risk of treatment failure, the 2.4% target lesion revascularization rate is the lowest reported for a superficial femoral artery device trial at 12 months. The significant sustained clinical improvement, the low rate of clinically driven target lesion revascularization, the absence of amputation, and the minimal incidence of thrombosis observed in the IN.PACT Admiral DCB group further underscore the clinical benefits of IN.PACT Admiral DCB and validate the favorable results generated by previous clinical trials. The IN.PACT SFA Trial data demonstrate an important therapeutic advantage over the existing alternative treatments for peripheral artery disease. DCB is an attractive alternative, because it offers the promise of improved patency in comparison with percutaneous transluminal angioplasty and a reduction in the need for stents. This is particularly important in the dynamic environment of the superficial femoral and popliteal arteries, where mechanical fatigue may lead to stent fracture and the increased risk of in-stent restenosis. The results of this trial support DCB as an important treatment option for patients with superficial femoral and popliteal artery disease.